Yeji
FDA approvalconf 0.85

crenessity — FDA approval

$NBIX · NEUROCRINE BIOSCIENCES INC
Event date
Date TBD
Sponsor runway
cash-flow +
$266.5M liquid

Evidence

“CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).”
Source: Press release · 2024-12-20View press release ↗

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

10 insiders · 0 buys · 3 sells
Exercise
2026-05-21
POON CHRISTINE A
Director
3,318 @ ——
Exercise
2026-05-21
LYONS GARY A
Director
1,659 @ ——
Exercise
2026-05-21
Mercier Johanna
Director
3,318 @ ——
Exercise
2026-05-21
SHERWIN STEPHEN A
Director
3,318 @ ——
Exercise
2026-05-21
Norwalk Leslie V
Director
1,659 @ ——
Exercise
2026-05-21
POPS RICHARD F
Director
3,318 @ ——
Exercise
2026-05-21
Sharp Shalini
Director
1,659 @ ——
Exercise
2026-05-21
MORROW GEORGE J
Director
3,318 @ ——
Exercise
2026-05-21
RASTETTER WILLIAM H
Director
3,318 @ ——
Exercise10b5-1
2026-05-19
GORMAN KEVIN CHARLES
Director
205,088 @ $43.24$8.87M
Sell10b5-1
2026-05-19
GORMAN KEVIN CHARLES
Director
245,088 @ $154.33$37.82M
Exercise10b5-1
2026-05-15
POPS RICHARD F
Director
15,000 @ $47.89$718K
Sell10b5-1
2026-05-15
POPS RICHARD F
Director
15,000 @ $157.65$2.36M
Sell10b5-1
2026-05-12
Norwalk Leslie V
Director
3,810 @ $155.01$591K
← All catalysts for $NBIX